JP2022547298A - 免疫療法組成物 - Google Patents

免疫療法組成物 Download PDF

Info

Publication number
JP2022547298A
JP2022547298A JP2022515475A JP2022515475A JP2022547298A JP 2022547298 A JP2022547298 A JP 2022547298A JP 2022515475 A JP2022515475 A JP 2022515475A JP 2022515475 A JP2022515475 A JP 2022515475A JP 2022547298 A JP2022547298 A JP 2022547298A
Authority
JP
Japan
Prior art keywords
saponin
protein
composition
adjuvant
hcmv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022515475A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022547298A5 (enExample
Inventor
エバンダー アンダーソン，デビッド
シュナイダー－オーラム，クリステン
Original Assignee
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
ヴァリエーション バイオテクノロジーズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グラクソスミスクライン バイオロジカルズ ソシエテ アノニム, ヴァリエーション バイオテクノロジーズ インコーポレイテッド filed Critical グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Publication of JP2022547298A publication Critical patent/JP2022547298A/ja
Publication of JP2022547298A5 publication Critical patent/JP2022547298A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13023—Virus like particles [VLP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
JP2022515475A 2019-09-09 2020-09-08 免疫療法組成物 Pending JP2022547298A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962897603P 2019-09-09 2019-09-09
US62/897,603 2019-09-09
PCT/EP2020/075002 WO2021048081A1 (en) 2019-09-09 2020-09-08 Immunotherapeutic compositions

Publications (2)

Publication Number Publication Date
JP2022547298A true JP2022547298A (ja) 2022-11-11
JP2022547298A5 JP2022547298A5 (enExample) 2023-09-15

Family

ID=72603444

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022515475A Pending JP2022547298A (ja) 2019-09-09 2020-09-08 免疫療法組成物

Country Status (9)

Country Link
US (2) US20210069321A1 (enExample)
EP (1) EP4028051A1 (enExample)
JP (1) JP2022547298A (enExample)
CN (1) CN114466659A (enExample)
BR (1) BR112022004228A2 (enExample)
CA (1) CA3092525A1 (enExample)
IL (1) IL290854A (enExample)
MX (1) MX2022002823A (enExample)
WO (1) WO2021048081A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019025104A2 (pt) 2017-05-30 2020-06-23 Glaxosmithkline Biologicals S.A. Método de fabricar um sistema de entrega não viral, sistema de entrega não viral, e, composição
EP3886901A1 (en) * 2018-11-29 2021-10-06 GlaxoSmithKline Biologicals S.A. Methods for manufacturing an adjuvant
KR20220038608A (ko) * 2019-05-31 2022-03-29 배리에이션 바이오테크놀로지스 아이엔씨. 다형성 교모세포종의 치료를 위한 면역치료 조성물
WO2021038508A1 (en) 2019-08-30 2021-03-04 Glaxosmithkline Biologicals Sa Jet mixing lipid nanoparticle manufacturing process
WO2023020994A1 (en) * 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
US20260224692A1 (en) * 2023-01-26 2026-08-06 The General Hospital Corporation T cell-directed anti-aging and anti-cancer vaccines against commensal cytomegalovirus
WO2025179112A1 (en) * 2024-02-23 2025-08-28 Curevo, Inc. Immunogenic compositions for the prevention of herpes zoster
WO2025180443A1 (en) * 2024-02-29 2025-09-04 Immunadd Inc. Adjuvant composition, pharmaceutical composition comprising the same, and method for preventing or treating disease caused by viral infection, bacterial infection, protozoal infection or cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011525191A (ja) * 2008-06-20 2011-09-15 デユーク・ユニバーシテイ 免疫応答を誘発するための組成物、方法およびキット
JP2015505299A (ja) * 2011-11-11 2015-02-19 ヴァリエーション バイオテクノロジーズ インコーポレイテッド サイトメガロウイルスの治療のための組成物及び方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
WO1988009797A1 (en) 1987-06-05 1988-12-15 The United States Of America, As Represented By Th Autocrine motility factors in cancer diagnosis and management
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
KR100310510B1 (ko) 1993-03-23 2002-07-04 장 스테판느 3-0-탈아세틸화모노포스포릴지질a를함유하는백신조성물
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
CA2252972C (en) 1998-11-26 2012-09-18 National Research Council Of Canada Serum-free production of recombinant proteins and adenoviral vectors
US6210922B1 (en) 1998-11-30 2001-04-03 National Research Council Of Canada Serum free production of recombinant proteins and adenoviral vectors
PT1284740E (pt) 2000-05-19 2008-07-09 Corixa Corp Tratamento profiláctico e terapêutico de doenças infecciosas, autoimunes e alérgicas com compostos à base de monossacáridos
CA2417806C (en) 2000-08-04 2011-05-10 Corixa Corporation New immunoeffector compounds
US6911434B2 (en) 2002-02-04 2005-06-28 Corixa Corporation Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
US6525028B1 (en) 2002-02-04 2003-02-25 Corixa Corporation Immunoeffector compounds
US7288640B2 (en) 2002-07-08 2007-10-30 Corixa Corporation Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
GB0323965D0 (en) * 2003-10-13 2003-11-19 Glaxosmithkline Biolog Sa Immunogenic compositions
EP2468300B1 (en) 2006-09-26 2017-12-20 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
CN103550764A (zh) * 2007-03-02 2014-02-05 葛兰素史密丝克莱恩生物有限公司 疫苗组合物及其在刺激免疫反应中的用途
SG190937A1 (en) 2010-12-14 2013-07-31 Glaxosmithkline Biolog Sa Mycobacterium antigenic composition
CN110088227B (zh) 2016-12-23 2023-01-10 库斯图姆多特公司 具有iii-v族核心和合金化ii-vi族外壳的量子点

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011525191A (ja) * 2008-06-20 2011-09-15 デユーク・ユニバーシテイ 免疫応答を誘発するための組成物、方法およびキット
JP2015505299A (ja) * 2011-11-11 2015-02-19 ヴァリエーション バイオテクノロジーズ インコーポレイテッド サイトメガロウイルスの治療のための組成物及び方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANNALS OF ONCOLOGY, 2015, VOL.26(SUPPLEMENT 8): VIII5-VIII14, JPN6024032962, ISSN: 0005529827 *
CLINICAL IMMUNOLOGY, 2017, VOL.183, PP.99-108, JPN6024032961, ISSN: 0005529828 *

Also Published As

Publication number Publication date
MX2022002823A (es) 2022-10-21
CN114466659A (zh) 2022-05-10
IL290854A (en) 2022-04-01
EP4028051A1 (en) 2022-07-20
US20230022956A1 (en) 2023-01-26
US20210069321A1 (en) 2021-03-11
WO2021048081A1 (en) 2021-03-18
CA3092525A1 (en) 2021-03-09
BR112022004228A2 (pt) 2022-05-31

Similar Documents

Publication Publication Date Title
CA3092525A1 (en) Immunotherapeutic compositions
CN102458457B (zh) 包含非离子等渗剂的佐剂组合物
US11248026B2 (en) Compositions and methods for treatment of cytomegalovirus
BE1023087B1 (fr) Antigenes du cytomegalovirus et leurs utilisations
JP4588296B2 (ja) キメラワクチン
US12419949B2 (en) Modified human cytomegalovirus proteins
JP6073031B2 (ja) インフルエンザ抗原のエンベロープウイルスベースのウイルス様粒子溶液を安定化させる方法
JP2016208979A (ja) 治療的免疫応答及び予防的免疫応答の両方を誘発するポリペプチド（複数可）保持ＣｙａＡ及びその使用
JP2021506767A (ja) Ｂ型肝炎免疫化レジメン及び組成物
JP2012529465A (ja) 低塩化ナトリウム濃度を有する免疫原性組成物
CA3206004A1 (en) Viral constructs for use in enhancing t-cell priming during vaccination
JP2022046617A (ja) 異種ポリペプチドを含むＣｙａＡベースのキメラタンパク質及び免疫応答の誘導におけるその使用
TW202227464A (zh) 治療阿茲海默氏症之多表位疫苗
JP2026082987A (ja) クロストリディオイデス（クロストリジウム）・ディフィシル（ｃｌｏｓｔｒｉｄｉｏｉｄｅｓ（ｃｌｏｓｔｒｉｄｉｕｍ）ｄｉｆｆｉｃｉｌｅ）に対する免疫応答を誘発するための免疫原性組成物および方法
JP2023541671A (ja) シヌクレイノパチーの処置のためのアルファ－シヌクレインワクチン
US20220305112A1 (en) Novel methods and uses
KR20230058101A (ko) 토코페롤-함유 스쿠알렌 에멀젼 아쥬반트를 갖는 covid-19 백신
JP2022553299A (ja) チクングニアウイルス様粒子ワクチンおよびその使用方法
US20250101067A1 (en) Modified human cytomegalovirus proteins
WO2024130009A1 (en) Compositions and methods of use thereof for the treatment of virally driven cancers
KR20250099770A (ko) 코로나바이러스에 대한 백신
JP2025038004A (ja) 多形性神経膠芽腫を処置するための免疫療法組成物
KR20260048548A (ko) 베타-레트로바이러스 Gag를 포함하는 키메라 VLP 형성 폴리펩타이드
Bungener et al. A virosomal immunization strategy against cervical cancer and pre-malignant cervical

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20221122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230906

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230906

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240820

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240823

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250218